Vitamin B6 status, deficiency and its consequences - An overview

Nutricion Hospitalaria

Volumn 22, Issue 1, 2007, Pages 7-24

  Spinneker, A ^b   Sola, R ^a   Lemmen, V ^a,b   Castillo, M J ^a   Pietrzik, K ^b   González Gross, Marcela ^a,b,c  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSIDAD POLITÉCNICA DE MADRID   (Spain)

Author keywords

Coenzyme; Elderly; Homocysteine; Vitamin B6; Vitamin B6 deficiency

Indexed keywords

HOMOCYSTEINE; METHIONINE; PLACEBO; PYRIDOXAL; PYRIDOXAL 5 PHOSPHATE; PYRIDOXAMINE; PYRIDOXAMINE PHOSPHATE; PYRIDOXAMINE PHOSPHATE OXIDASE; PYRIDOXINE; TRYPTOPHAN; VITAMIN B GROUP;

ALZHEIMER DISEASE; AMINO ACID METABOLISM; BIOCHEMISTRY; CANCER; CARDIOVASCULAR DISEASE; CHEMICAL STRUCTURE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MEGADOSE; ELDERLY CARE; HOMOCYSTINURIA; HUMAN; INTOXICATION; IRON DEFICIENCY ANEMIA; LIVER CIRRHOSIS; MICROCYTIC ANEMIA; NEUROTRANSMISSION; NUTRITIONAL STATUS; PERIPHERAL NEUROPATHY; PYRIDOXINE DEFICIENCY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSORY NEUROPATHY; SIDEROBLASTIC ANEMIA; VITAMIN BLOOD LEVEL; VITAMIN DEFICIENCY; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION; METABOLISM; PATHOPHYSIOLOGY;

HUMANS; VITAMIN B 6; VITAMIN B 6 DEFICIENCY;

EID: 33847392009     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: None     Document Type: Review

References (180)

1. Bässler KH, Golly I, Loew D, Pietrzik K. Vitamin-Lexikon. Urban & Fischer. Pages. München Jena, 3. ed. 2002.
2. 12, pantothenic acid, biotin, and choline. National Academy Press. Washington DC, 1998.
3. Ink SL, Mehansho H, Henderson LVM. The binding of pyridoxal to haemoglobin. J Biol Chem 1982; 257:4753-4757.
4. 6 and plasma pyridoxal-P clearance: metabolic balance studies in humans. J Lab Clin Med 1985; 106:491-497.
5. 6. Eur J Clin Nutr 1997; 51(Supl. 1):S43-48.
6. Snell EE. in Fourth international Congress of Biochemistry-Vitamin Metabolism 1958; 250-265 (Pergamon, New York).
7. 6 requirements. Proceedings of a Workshop 1978; 111-128 (National Academy Press, Washington, DC).
8. 6 in men. J Nutr 1980; 110:275-285.
9. 6-dependent enzymes. Curr Opin Struct Biol 1998; 8:759-769.
10. 6 in mental functioning: a review of controlled trials in humans. Biol Psychiatry 1991; 29:931-941.
11. Selhub J, Bagley LC, Miller J, Rosenberg IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 2000; 71:614S-620S.
12. Mudd SH et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985; 37:1-31.
13. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992; 55:131-138.
14. Leklem JE. Modern Nutrition in Health and Disease. Lea and Febiger. Pages. Philadelphia. 9. ed. 1998.
15. 6 metabolism in chronic alcohol abuse. Pyridoxal phosphate levels in plasma and the effects of acetaldehyde on pyridoxal phosphate synthesis and degradation in human erythrocytes. J Clin Invest 1974; 53:693-704.
16. 6 supplementation during pregnancy: a prospective study. Am J Clin Nutr 1978; 29:1376-1383.
17. 6. A status report. J Nutr 1990; 120(Supl. 11):1503-1507.
18. 6. Int J Vitam Nutr Res 1993; 63:278-282.
19. 6. Am J Clin Nutr 1997; 66:1379-1387.
20. 6 status in man. Am J Clin Nutr 1970; 23:696-702.
21. 6. Am J Clin Nutr 1975; 28:10-19.
22. 6 requirements and recommendations. Eur J Clin Nutr 1989; 43:289-309.
23. 6 requirements. Proceedings of a Workshop. 1980; 111-128 (National Academy Press, Washington, DC).
24. 6 deficiency on carbohydrate metabolism. Am J Clin Nutr 1975; 28:872-878.
25. 6 requirement of young adult women. Am J Clin Nutr 1971; 24:1028-1041.
26. 6. Am J Clin Nutr 1977; 30:1122-1128.
27. 6 depletion in adult man on the excretion of cystathionine and other methionine metabolites. J Nutr 1970; 100:110-116.
28. 6 deficiency. J Nutr 1974; 104:1348-1355.
29. 6 nutrition, analysis and status assessment. Plenum Press. Pages. New York. 1981.
30. 6 nutrition, analysis and status assessment. Plenum Press. Pages. New York. 1981.
31. Graham IM et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277:1775-1781.
32. Rosenberg IH, Miller JW. Nutritional factors in physical and cognitive functions of elderly people. Am J Clin Nutr 1992; 55:1237S-1243S.
33. Bottomley SS. Wintrobes clinical haematology. Lea & Febiger. Pages. Philadelphia. 1993.
34. 6 deficiency. Am J Clin Nutr 1967; 20:547-561.
35. 6 deficiency anemia. Schweiz Med Wochenschr 1975; 105:1319-1324.
36. Fishman SM, Christian P, West KP. The role of vitamins in the prevention and control of anaemia. Public Health Nutr 2000; 3:125-150.
37. Stoerk HC. Effects of calcium deficiency and pyridoxine deficiency on thumic atropy (accidental involution). Proc Soc Exp Biol Med 1946; 62:90-96.
38. Stoerk HC, Eisen HN. Suppression of circulating antibodies by pyridoxine deficiency. Proc Soc Exp Biol Med 1946; 62: 88-89.
39. Grimble RF. Modification of inflammatory aspects of immune function by nutrients. Nutr Res 1998; 82:1297-1317.
40. 6 deficiency impairs interleukin 2 production and lymphocyte proliferation in elderly adults. Am J Clin Nutr 1991; 53:1275-1280.
41. Talbott MC, Miller LT, Kerkvliet NI. Pyridoxine supplementation: effect on lymphocyte responses in elderly persons. Am J Clin Nutr 1987; 46:659-664.
42. 6 on oxygen radicals, mitochondrial membrane potential, and lipid peroxidation in H2O2-treated U937 monocytes. Free Radic Biol Med 2004; 36:423-428.
43. 6 deficiency but does not improve inflammation in patients with rheumatoid arthritis. Arthritis Res Ther 2005; 7:R1404-R1411.
44. 6. Arthritis Res Ther 2005; 7:R1254-R1262.
45. Stabler SP, Sampson DA, Wang LP, Allen RH. Elevations of serum cystathionine and total homocysteine in pyridoxine-, folate-, and cobalamin-deficient rats. J Nutr Biochem 1997; 8:279-289.
46. Blount BC et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA 1997; 94:3290-3295.
47. Choi SW, Kim YI, Weitzel JN, Mason JB. Folate depletion impairs DNA excision repair in the colon of the rat. Gut 1998; 43:93-99.
48. 6. Am J Clin Nutr 1998; 67:208-220.
49. Jarrard DF, Bova GS, Isaacs WB. DNA methylation, molecular genetic, and linkage studies in prostate cancer. Prostate (Supl.) 1996; 6:36-44.
50. Jones PA, Buckley JD. The role of DNA methylation in cancer. Adv Cancer Res 1990;54: 1-23.
51. Eto I, Krumdieck CL. Essential nutrients in carcinogenesis. Plenum Press. Pages. New York. 1985.
52. 6 and cognitive development: recent research findings from human and animal studies. Nutr Rev 1993; 51:193-198.
53. 6. Alan R. Liss Inc. Pages. New York. 1988.
54. Davis BA, Cowing BE. Pyridoxal supplementation reduces cell proliferation and DNA synthesis in estrogen-dependent and -independent mammary carcinoma cell lines. Nutr Cancer 2000; 38:281-286.
55. 6 diet suppress azoxymethane-induced colon tumorigenesis in mice by reducing cell proliferation. J Nutr 2001; 131:2204-2207.
56. 6 suppresses colon tumorigenesis, 8-hydroxyguanosine, 4-hydroxynonenal, and inducible nitric oxide synthase protein in azoxymethane-treated mice. J Nutr Sci Vitaminol (Tokyo) 2002; 48:65-68.
57. 6 and the risk of colorectal cancer and adenoma in women. J Natl Cancer Inst 2005; 97:684-692.
58. 6 may help prevent colorectal cancer in women. A dietary component is poised to join a list of strategies that help lower our risk for this largely preventable cancer. Harv Womens Health Watch 2005; 12:1-2.
59. Slattery ML et al. Associations between dietary intake and Kiras mutations in colon tumors: a population-based study. Cancer Res 2000; 60:6935-6941.
60. Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME. Nutritional risks and colorectal cancer in a Portuguese population. Nutr Hosp 2005; 20:165-172.
61. Stolzenberg-Solomon RZ et al. Pancreatic cancer risk and nutrition-related methyl-group availability indicators in male smokers. J Natl Cancer Inst 1999; 91:535-541.
62. 6 deficiency affects rat pancreatic digestive enzyme and glutathione reductase activities. J Nutr 1995; 125:20-25.
63. Chu M, Rehfeld JF, Borch K. Chronic endogenous hypercholecystokininemia promotes pancreatic carcinogenesis in the hamster. Carcinogenesis 1997; 18:315-320.
64. Howatson AG, Carter DC. Pancreatic carcinogenesis-enhancement by cholecystokinin in the hamster-nitrosamine model. Br J Cancer 1985; 51:107-114.
65. Farber E, Popper H. Production of acute pancreatitis with ethionine and its prevention by methionine. Proc Soc Exp Biol Med 1950; 74:838-840.
66. Goldberg RC, Chaikoff IL, Dodge AH. Destruction of pancreatic acinar tissue by DL-ethionine. Proc Soc Exp Biol Med 1950; 74:869-872.
67. Lombardi B, Estes LW, Longnecker DS. Acute hemorrhagic pancreatitis (massive necrosis) with fat necrosis induced in mice by DL-ethionine fed with a choline-deficient diet. Am J Pathol 1975; 79:465-480.
68. Kaaks R, Tuyns AJ, Haelterman M, Riboli E. Nutrient intake patterns and gastric cancer risk: a case-control study in Belgium. Int J Cancer 1998; 78:415-420.
69. Zhang ZF et al. Adenocarcinomas of the esophagus and gastric cardia: the role of diet. Nutr Cancer 1997; 27:298-309.
70. Harrison LE, Zhang ZF, Karpeh MS, Sun M, Kurtz RC. The role of dietary factors in the intestinal and diffuse histologic subtypes of gastric adenocarcinoma: a case-control study in the US. Cancer 1997; 80:1021-1028.
71. Negri E et al. Selected micronutrients and oral and pharyngeal cancer. Int J Cancer 2000; 86:122-127.
72. 12, and folate with lung cancer risk in older men. Am J Epidemiol 2001; 153:688-694.
73. Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT. A case-control study of diet and prostate cancer. Br J Cancer 1997; 76:678-687.
74. 6) and breast cancer. Cancer Epidemiol Biomarkers Prev 1999; 8:209-217.
75. 12, homocysteine, and risk of breast cancer. J Natl Cancer Inst 2003; 95:373-380.
76. 6 deficiency in monkeys. Am J Clin Nutr 1956; 4:346-353.
77. 6 deficiency in the syrian hamster. J Nutr 1949; 38:131-153.
78. 6 deficiency in aged and weanling rats with hind leg gait analysis. J Am Coll Nutr 1990; 9:120-127.
79. McCormick DB. Modern nutrition in health and disease. Lea and Febiger. Pages. Philadelphia. 9. ed. 1999.
80. Carson NA, Dent CE, Field CM, Gaull GE. Homocystinuria: Clinical and Pathological Review of Ten Cases. J Pediatr 1965; 66:565-583.
81. Valle D, Pai GG, Thomas GH, Pyeritz RE. Homocystinuria due to a cystathionine beta-synthase deficiency: clinical manifestations and therapy. Johns Hopkins Med J 1980; 146:110-117.
82. 6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996; 63:306-314.
83. Goodwin JS, Goodwin JM, Garry PJ. Association between nutritional status and cognitive functioning in a healthy elderly population. JAMA 1983; 249:2917-2921.
84. 6 supplementation in elderly men: effects on mood, memory, performance and mental effort. Psychopharmacology (Berl) 1992; 109:489-496.
85. Chandra RK. Effect of vitamin and trace-element supplementation on cognitive function in elderly subjects. Nutrition 2001; 17:709-712.
86. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord 1999; 10:12-20.
87. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998; 13:235-239.
88. Bell IR et al. B complex vitamin patterns in geriatric and young adult inpatients with major depression. J Am Geriatr Soc 1991; 39:252-257.
89. Miller JW, Green R, Allen LH, Mungas DM, Haan MN. Homocysteine correlates with cognitive function in the Sacramento Area Latino Study of Aging (SALSA). FASEB J 1999; 13:A374.
90. Budge M et al. Plasma total homocysteine and cognitive performance in a volunteer elderly population. Ann N Y Acad Sci 2000; 903:407-410.
91. Nilsson K, Gustafson L, Hultberg B. The plasma homocysteine concentration is better than that of serum methylmalonic acid as a marker for sociopsychological performance in a psychogeriatric population. Clin Chem 2000; 46:691-696.
92. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2001; 73:927-933.
93. Jensen E, Dehlin O, Erfurth EM. Plasma homocysteine in 80-year-olds: relationships to medical, psychological and social variables. Arch Gerontol Geriatr 1998; 26:215-226.
94. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-1057.
95. Kalmijn S et al. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol 1999; 150:283-289.
96. Ravaglia G et al. Elevated plasma homocysteine levels in centenarians are not associated with cognitive impairment. Mech Ageing Dev 2000; 121:251-261.
97. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114:473-501.
98. Paulionis L, Kane SL, Meckling KA. Vitamin status and cognitive function in a long-term care population. BMC Geriatr 2005; 5-16.
99. 6, and vascular disease in AD patients. Neurology 2002; 58:1471-1475.
100. Fassbender K et al. Homocysteine in cerebral macroangiography and microangiopathy. Lancet 1999; 353:1586-1587.
101. 12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55:1449-1455.
102. 6 levels are associated with white matter lesions in Alzheimer's disease. J Am Geriatr Soc 2005; 53:1073-4.
103. 6 and infantile convulsions: a first approximation of requirements of pyridoxine in infants. Pediatrics 1957;20: 33-44.
104. Coursin DB. Convulsive seizures in infants with pyridoxinedeficient diet. J Am Med Assoc 1954; 154:406-408.
105. 6 and brain function in animals and man. Ann N Y Acad Sci 1969; 166:7-15.
106. Canham JE, Nunes WT, Eberlin EW. Proceedings of the Sixth International Congress on Nutrition 537 1964. E & S Livingstone Ltd. London.
107. 6 requirements and function. Ann N Y Acad Sci 1969; 166:16-29.
108. 6 deficiency and preconvulsant activity in brain. Nutr Rev 1988; 46:358-60.
109. 6: its role in health and disease. Alan R LIss Inc. Pages. New York. 1985.
110. Guilarte TR, Wagner HN Jr. Increased concentrations of 3-hydroxykynurenine in vitamin B6 deficient neonatal rat brain. J Neurochem 1987; 49:1918-1926.
111. 6 deficiency on specific regions of developing rat brain: the extrapyramidal motor system. J Nutr 1983; 113:746-754.
112. Dakshinamurti K, & Stephens MC. Pyridoxine deficiency in the neonatal rat. J Neurochem 1969; 16:1515-22.
113. Stephens MC, Havlicek V, Dakshinamurti K. Pyridoxine deficiency and development of the central nervous system in the rat. J Neurochem 1971; 18:2407-2416.
114. Meldrum BS. Epilepsy and gamma-aminobutyric acid-mediated inhibition. Int Rev Neurobiol 1975; 17:1-36.
115. 6. Am J Clin Nutr 1995; 61:1091-1101.
116. 6 deficiency in elderly patients on chronic peritoneal dialysis. Adv Perit Dial 2000; 16:308-312.
117. Gorson KC, Ropper AH. Additional causes for distal sensory polyneuropathy in diabetic patients. J Neurol Neurosurg Psychiatry 2006; 77:354-358.
118. Rinehard JF, Greenberg LD. Arteriosclerotic lesions in pyridoxine-deficient monkeys. Am J Pathol 1949; 25:481-491.
119. 12, and folate. Am J Epidemiol 1996; 143:845-859.
120. 6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279:359-364.
121. Robinson K et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92:2825-2830.
122. Folsom AR et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98:204-210.
123. Stampfer MJ et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877-881.
124. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2693-2698.
125. Jacques PF et al. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001; 73:613-621.
126. Saw SM et al. Genetic, dietary, and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore. Am J Clin Nutr 2001; 73:232-239.
127. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49:31-62.
128. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131:363-375.
129. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338:1042-1050.
130. 6 down-regulates the expression of human GPIIb gene. J Nutr Sci Vitaminol (Tokyo) 1999; 45:471-479.
131. 6 vitamers inhibits human platelet aggregation. J Nutr 2002; 132:3603-3606.
132. Kobzar G, Mardia V. Inhibition of platelet aggregation by pyridoxine. Nutr Res 2002; 22:997-1001.
133. 6 (pyridoxine) deficiency on lung elastin cross-linking in perinatal and weanling rat pups. Biochem J 1985; 229:153-160.
134. Vasdev S, Longerich L, Singal P. Nutrition and hypertension. Nutr Res 2002; 22:111-123.
135. 6 are independently associated with a heightened risk of deep-vein thrombosis. Circulation 2001; 104:2442-2446.
136. Mudd SH, Levy HL, Skovby F. The metabolic and molecular basis of inherited disease. McGraw-Hill: Pages. New York. 1995.
137. 6 is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 2001; 103:2788-2791.
138. Herrmann W, Knapp JP. Hyperhomocysteinemia: a new risk factor for degenerative diseases. Clin Lab 2002; 48:471-481.
139. 12, folic acid and carotene. Euronut SENECA investigators. Eur J Clin Nutr 1991; 45(Supl. 3):63-82.
140. 6: Its role in Health and Disease. Alan R Liss Inc. Pages. New York. 1985.
141. 6 levels due to dopamine. Vet Hum Toxicol 1991; 33:118-121.
142. Brophy MH, Siiteri PK. Pyridoxal phosphate and hypertensive disorders of pregnancy. Am J Obstet Gynecol 1975; 121:1075-1079.
143. 6 status and metabolism in pregnant women and oral contraceptive agent users. Am J Clin Nutr 1980; 28:739-747.
144. Bassler KH. Megavitamin therapy with pyridoxine. Int J Vitam Nutr Res 1988; 58:105-118.
145. Dudman NP et al. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler Thromb 1993; 13:1253-1260.
146. Franken DG, Boers GH, Blom HJ, Trijbels FJ, Kloppenborg PW. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994; 14:465-470.
147. Wilcken DE, Gupta VJ, Betts AK. Homocysteine in the plasma of renal transplant recipients: effects of cofactors for methionine metabolism. Clin Sci (Lond) 1981; 61:743-749.
148. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988; 48:215-221.
149. Brattstrom L et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990; 81:51-60.
150. Arnadottir M et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993; 40:236-240.
151. Ubbink JB et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994; 124:1927-1933.
152. Bostom AG et al. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med 1997; 127:1089-1092.
153. 6 supplementation and plasma homocysteine concentrations in healthy young women. Int J Vitam Nutr Res 1998; 68:98-103.
154. 6 supplementation. Ann Nutr Metab 2001; 45:255-258.
155. Lakshmi AV, Ramalakshmi BA. Effect of pyridoxine or riboflavin supplementation on plasma homocysteine levels in women with oral lesions. Natl Med J India 1998; 11:171-172.
156. 6 reduce concentrations of serum folate. Scand J Clin Lab Invest 1999; 59: 139-146.
157. Bronstrup A, Hages M, Pietrzik K. Lowering of homocysteine concentrations in elderly men and women. Int J Vitam Nutr Res 1999; 69:187-193.
158. 6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. Am J Clin Nutr 2001; 73: 759-764.
159. 12 concentrations. Gerontology 2001; 47:30-35.
160. 6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002; 288:973-979.
161. McKay DL, Perrone G, Rasmussen H, Dallal G, Blumberg JB. Multivitamin/mineral supplementation improves plasma B-vitamin status and homocysteine concentration in healthy older adults consuming a folate-fortified diet. J Nutr 2000; 130:3090-3096.
162. Deutsche Gesellschaft für Ernährung: Ernährungsbericht 2004. Deutsche Gesellschaft für Ernährung e.V. Pages. Bonn. 2004.
163. D-A-CH: Reference values for nutrient intakes. Umschau/Braus. Pages. Frankfurt am Main. 1. ed. 2000.
164. 6 deficiency elevates serum insulin in elderly subjects. Ann N Y Acad Sci 1990; 585:531-533.
165. Russell RM. Micronutrient requirements of the elderly. Nutr Rev 1992; 50:463-466.
166. 6 in elderly people: a nationwide nutritional survey (Dutch Nutritional Surveillance System). Am J Clin Nutr 1989; 50:391-399.
167. Hamfelt A. Age variations of vitamin B6 metabolism in man. Clin Chim Acta 1964; 10:4854.
168. 6 load. Am J Clin Nutr 1988; 48:1284-1290.
169. 6 status of institutionalized and non-institutionalized aged. Int J Vitam Nutr Res 1977; 47:364-372.
170. 6 deficiencies in geriatric patients, measured by coenzyme stimulation of enzyme activities. Clin Chim Acta 1975; 61:151-162.
171. 6 in Hungary. Lancet 1998; 352:1225.
172. Schaumburg H et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med 1983; 309:445-448.
173. Bear RL. Cutaneous skin changes probably due to pyridoxine abuse. J Am Acad Dermatol 1984; 10:527-528.
174. Bredesen E, Parry GJ. Pyridoxine neuropathy. Neurology 1984; 34:136.
175. de Zegher F, Przyrembel H, Chalmers RA, Wolff ED, Huijmans JG. Successful treatment of infantile type I primary hyperoxaluria complicated by pyridoxine toxicity. Lancet 1985; 2:392-393.
176. Friedman MA, Resnick JS, Baer RL. Subepidermal vesicular dermatosis and sensory peripheral neuropathy caused by pyridoxine abuse. J Am Acad Dermatol 1986; 14:915-917.
177. 6 (pyridoxal phosphate): chemical, biochemical and medical aspects. Wiley Interscience. Pages. New York. 1986.
178. Dalton K, Dalton MJ. Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand 1987; 76:8-11.
179. 6. Current topics in nutrition and Disease. Alan R Liss. Pages. New York. 1988.
180. 6: its role in health and disease. Current topics in nutrition and disease. Alan R. Liss. Pages. New York. 1985.